LeadershipLeadership Transition at BenevolentAI

BenevolentAI (Euronext Amsterdam: BAI), a pioneering force in applying advanced artificial intelligence (AI) to expedite biopharma drug discovery, has announced changes to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors.

In a strategic move aimed at enhancing operational efficiency and aligning with ambitious growth objectives, the Board conducted a thorough leadership review. As a result, Ms. Catherine Isted has decided to step down from her role as Chief Financial Officer, for which the Board acknowledges her significant contributions. Mr. Tom Holgate, who brings nearly seven years of experience at BenevolentAI, will continue in his role as Group Finance Director, ensuring seamless continuity and leveraging his deep understanding of the company’s financial landscape to spearhead key financial initiatives.

BenevolentAI is intensifying its focus on seizing opportunities within the rapidly evolving ‘techbio’ sector. The company’s recent achievement includes the successful integration of a novel Systemic Lupus Erythematosus target into AstraZeneca’s portfolio, marking a notable milestone and the second major collaboration achievement with AstraZeneca this year.

The Board’s review has underscored the importance of fostering a dynamic and entrepreneurial leadership approach across business development activities and internal management structures. These strategic adjustments aim to bolster the company’s market position in AI-driven drug discovery, expedite internal pipeline development, and forge new strategic alliances.

Dr. Joerg Moeller, Chief Executive Officer of BenevolentAI, expressed his appreciation, stating, “It has been a privilege to collaborate with Catherine, and I extend my gratitude for her dedication and contributions during her tenure as Chief Financial Officer. As leaders in leveraging advanced AI for biopharma innovation, at BenevolentAI, we remain steadfast in delivering shareholder value and pioneering novel therapies for patients grappling with severe medical conditions.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter